WEE1 and cytomegalovirus infection: Maribavir, an inhibitor of CMV-specific UL97 protein kinase, was approved by the FDA in November 2021 as the first drug for treating adult and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant CMV infection or disease that does not respond to available antiviral treatment for CMV (8).